Evidence map›Paper›PMID 20935067›Full record

ArticleRNA (New York, N.Y.)2010

Antisense tools for functional studies of human Argonaute proteins.

Alessandra Mescalchin, Anke Detzer, Ulrike Weirauch, Maximilian J Hahnel, Christina Engel, Georg Sczakiel

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in RNA (New York, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. miRNA goes nuclear.RNA biology · 2012
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alessandra MescalchinInstitute of Molecular Medicine, University of Luebeck, Center for Structural and Cell Biology in Medicine (CSCM), D-23538 Luebeck, Germany. mescalchin@imm.uni-luebeck.de
Anke Detzer
Ulrike Weirauch
Maximilian J Hahnel
Christina Engel
Georg Sczakiel
University of Lübeck · DEInstitute for Integrative and Experimental Genomics · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Argonaute proteins play essential roles in development and cellular metabolism in many organisms, including plants, flies, worms, and mammals. Whereas in organisms such as Caenorhabditis elegans and Arabidopsis thaliana, creation of Argonaute mutant strains allowed the study of their biological functions, in mammals the application of this approach is limited by its difficulty and in the specific case of Ago2 gene, by the lethality of such mutation. Hence, in human cells, functional studies of Ago proteins relied on phenotypic suppression using small interfering RNA (siRNA) which involves Ago proteins and the RNA interference mechanism. This bears the danger of undesired or unknown interference effects which may lead to misleading results. Thus, alternative methods acting by different regulatory mechanisms would be advantageous in order to exclude unspecific effects. The knockdown may be achieved by using specific antisense oligonucleotides (asONs) which act via an RNase H-dependent mechanism, not thought to interfere with processes in which Agos are involved. Different functional observations in the use of siRNA versus asONs indicate the relevance of this assumption. We developed asONs specific for the four human Agos (hAgos) and compared their activities with those obtained by siRNA. We confirm that hAgo2 is involved in microRNA (miRNA)- and in siRNA-mediated silencing pathways, while the other hAgos play a role only in miRNA-based gene regulation. Using combinations of asONs we found that the simultaneous down-regulation of hAgo1, hAgo2, and hAgo4 led to the strongest decrease in miRNA activity, indicating a main role of these proteins.

Indexed as

Argonaute ProteinsCells, CulturedDose-Response Relationship, DrugDown-RegulationEfficiencyEukaryotic Initiation Factor-2Eukaryotic Initiation FactorsHumansInhibitory Concentration 50Oligoribonucleotides, AntisenseRNA InterferenceRNA, Small InterferingSubstrate SpecificityTransfectionAGO1 protein, humanAGO2 protein, humanArgonaute ProteinsEukaryotic Initiation Factor-2Eukaryotic Initiation FactorsOligoribonucleotides, AntisenseRNA, Small Interfering

Identifiers

PMID20935067
PMCPMC2995413
OpenAlexW2128109474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.